Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)

被引：6
|
作者：
Janne, P. A. [1 ]
Wu, Y-L. [2 ,3 ]
Kato, T. [4 ]
Besse, B. [5 ]
Peters, S. [6 ]
Nguyen, D. [7 ]
Berg, D. [8 ]
Lin, J. [9 ]
Feng, Z. [10 ]
Mok, T. [11 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[3] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[4] Kanagawa Canc Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
[5] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[6] Ctr Hosp Univ Vaudois CHUV, Multidisciplinary Oncol Ctr, Lausanne, Switzerland
[7] Pacific Shores Med Grp, Hematol & Oncol, Long Beach, CA USA
[8] Millennium Pharmaceut Inc, Oncol Clin Res & Dev, Cambridge, MA USA
[9] Millennium Pharmaceut Inc, Oncol Stat, Cambridge, MA USA
[10] Millennium Pharmaceut Inc, Clin Sci, Cambridge, MA USA
[11] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1726
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1412TiP
引用
收藏
页码：S892 / S893
页数：2
相关论文
共 50 条
  • [1] Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins)
    Riely, G. J.
    Neal, J. W.
    Camidge, D. R.
    Spira, A.
    Piotrowska, Z.
    Horn, L.
    Costa, D. B.
    Tsao, A.
    Patel, J.
    Gadgeel, S.
    Bazhenova, L.
    Zhu, V. W.
    West, H.
    Mekhail, T.
    Gentzler, R.
    Nguyen, D.
    Bunn, V.
    Jin, S.
    Feng, Z.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S815 - S816
  • [2] Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
    Zhang, Shannon S.
    Zhu, Viola W.
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 61 - 65
  • [3] Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions
    Janne, Pasi A.
    Neal, Joel W.
    Camidge, D. R.
    Spira, Alexander
    Piotrowska, Zofia
    Horn, Leora
    Costa, Daniel B.
    Tsao, Anne
    Patel, Jyoti
    Gadgeel, Shirish
    Bazhenova, Lyudmila
    Zhu, Viola W.
    West, Howard
    Vincent, Sylvie
    Zhu, Jian
    Li, Shuanglian
    Riely, Gregory J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
    Janne, Pasi A.
    Neal, Joel W.
    Camidge, D. Ross
    Spira, Alexander I.
    Piotrowska, Zofia
    Horn, Leora
    Costa, Daniel Botelho
    Tsao, Anne S.
    Patel, Jyoti D.
    Gadgeel, Shirish M.
    Bazhenova, Lyudmila
    Zhu, Viola Weijia
    West, Howard
    Vincent, Sylvie
    Zhu, Jian
    Li, Shuanglian
    Riely, Gregory J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Mobocertinib (TAK-788) in metastatic EGFR Exon 20 Insertions (ex20ins) + NSCLC: Results of platinum-experienced Patients and the EXCLAIM Cohort of a Phase 1/2 Study
    Misch, D.
    Ramalingam, S.
    Zhou, C.
    Kim, T. M.
    Yang, J. C.
    Riely, G.
    Mekhail, T.
    Nguyen, D.
    Campelo, Garcia M. R.
    Felip, E.
    Bunn, V.
    Lin, H.
    Zhang, P.
    Jaenne, P.
    Kaur, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 96 - 97
  • [6] Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions
    Riely, G.
    Neal, J.
    Camidge, D. R.
    Spira, A.
    Piotrowska, Z.
    Horn, L.
    Costa, D.
    Tsao, A.
    Patel, J.
    Gadgeel, S.
    Bazhenova, L.
    Zhu, V.
    West, H.
    Vincent, S.
    Zhu, J.
    Jin, S.
    Zhang, S.
    Li, S.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S412 - S413
  • [7] EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy
    Shah, Manan P.
    Aredo, Jacqueline, V
    Padda, Sukhmani K.
    Ramchandran, Kavitha J.
    Wakelee, Heather A.
    Das, Millie S.
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2022, 23 (02) : E148 - E153
  • [8] Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
    Garcia Campelo, Maria Rosario
    Zhou, Caicun
    Ramalingam, Suresh S.
    Lin, Huamao M.
    Kim, Tae Min
    Riely, Gregory J.
    Mekhail, Tarek
    Nguyen, Danny
    Goodman, Erin
    Mehta, Minal
    Popat, Sanjay
    Janne, Pasi A.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (01)
  • [9] FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions
    Spira, A. I.
    Cho, B. C.
    Felip, E.
    Garon, E. B.
    Goto, K.
    Johnson, M. L.
    Leighl, N. B.
    Passaro, A.
    Planchard, D.
    Popat, S.
    Yang, J.
    Lu, X.
    Jiang, Y.
    Huang, J.
    Lam, M.
    Kowanetz, M.
    Wang, S.
    Le, J.
    Hsu, J. Y.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S339 - S339
  • [10] Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort
    Garcia Campelo, M. R.
    Zhou, C.
    Ramalingam, S.
    Lin, H.
    Kim, T.
    Riely, G.
    Mekhail, T.
    Nguyen, D.
    Goodman, E.
    Le, K.
    Mehta, M.
    Popat, S.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S960 - S961
12345